You are here

GSK

Science finally figured out how to make effective RSV vaccines. Will seniors care?

Science finally figured out how to make effective RSV vaccines. Will seniors care?

Stat

Flag link:

Heightened US antitrust fears rattle biopharma

Heightened US antitrust fears rattle biopharma

EP Vantage

Horizon Therapeutics

Prometheus Biosciences

Flag link:

GSK to raise $1B by selling partial stake in former consumer health unit Haleon

GSK to raise $1B by selling partial stake in former consumer health unit Haleon

Fierce Pharma

consumer health

Flag link:

GSK tees up Pfizer fight with pivotal meningitis vaccine data

GSK tees up Pfizer fight with pivotal meningitis vaccine data

Fierce Biotech

Flag link:

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

BioSpace

Gilead Sciences

Flag link:

Iteos – and GSK – keep the faith

Iteos – and GSK – keep the faith

EP Vantage

iTeos Therapeutics

Flag link:

Cut Short by RSV: GSK’s compelling ad ties into recent FDA approval

Cut Short by RSV: GSK’s compelling ad ties into recent FDA approval

Medical Marketing and Media

Flag link:

GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine

GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine

Clinical Trials Arena

Flag link:

FDA approves first RSV vaccine, clearing GSK’s Arexvy for older adults

FDA approves first RSV vaccine, clearing GSK’s Arexvy for older adults

BioPharma Dive

Flag link:

The race for gold: Closing in on the first RSV vaccine

The race for gold: Closing in on the first RSV vaccine

Pharmaphorum

Moderna Therapeutics

Flag link:

'More in the hopper': European Big Pharmas hint M&A could ramp up

'More in the hopper': European Big Pharmas hint M&A could ramp up

Fierce Biotech

Flag link:

GSK's RSV vaccine first to get EU regulator's nod

GSK's RSV vaccine first to get EU regulator's nod

Reuters

Flag link:

As FDA decision nears, GSK projects 'Shingrix-like' sales for its RSV vaccine prospect

As FDA decision nears, GSK projects 'Shingrix-like' sales for its RSV vaccine prospect

Fierce Pharma

Flag link:

Big pharma’s biggest spenders revealed: 2022 edition

Big pharma’s biggest spenders revealed: 2022 edition

EP Vantage

Bristol Myers Squibb

Flag link:

GSK faces strike threat in UK, again, after workers pan pay raise

GSK faces strike threat in UK, again, after workers pan pay raise

Fierce Pharma

Flag link:

Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A

Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A

Fierce Pharma

Prometheus Biosciences

Flag link:

GSK coughs up $2B for Bellus Health

GSK coughs up $2B for Bellus Health

Medical Marketing and Media

Flag link:

GSK's gepotidacin shows potential in urinary tract infections

GSK's gepotidacin shows potential in urinary tract infections

Marketscreener

Flag link:

Pages